PADI2

The science behind Lucid MS Lucid MS, also known by its research designation Lucid 21-302, is built around a different theory of how to target MS progression.

Rather than treating the immune system as the primary target, the compound is designed to act on PAD2, an enzyme expressed in the central nervous system that catalyzes a chemical process called citrullination of myelin proteins.

That citrullination process is believed to contribute directly to the breakdown of myelin, making PAD2 inhibition a plausible way to interrupt disease progression at its source.

The compound is a patented new chemical entity that has been studied for more than 11 years, with underlying research published in peer-reviewed journals, including the Journal of Medicinal Chemistry and the Proceedings of the National Academy of Sciences.

In preclinical animal models, the company reports that Lucid MS accelerated functional recovery, preserved myelin and reduced axonal degradation, all without suppressing the immune system, distinguishing its proposed mechanism from nearly every currently marketed MS drug.